

AVI BioPharma

[View the current AVI BioPharma Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/1121-AVI+BioPharma.html)

(<http://www.bioportfolio.com/bi corporate/1121-AVI+BioPharma.html>)

Contact Details:

ONE SW COLUMBIA STREET, SUITE 1105

Portland

97258

United States of America

Tel: 503 227 0554

Fax: 503 227 0751

Email: avi@avibio.com

AVI BioPharma is an emerging biopharmaceutical company and a pioneer in the development of therapeutic products based upon three platform technologies: - therapeutic cancer vaccines, - gene-targeted drugs (antisense), and, - drug delivery technologies.

The Company focuses its three platform technologies on two important clinical areas, cancer and cardiovascular disease. The Company is in late-stage development with Avicine, its cancer vaccine, which the Company believes may be applicable to many cancer types. The Company also has developed Neu-Genes(R), a patented class of antisense compounds, which may prove to be useful in the treatment of a wide range of human diseases. The Company has developed a new intracellular drug delivery technology, CytoPorter(TM), which may be useful with many FDA-approved drugs as well as with drugs in development.

Recent Publications by AVI BioPharma:



- [Cationic phosphorodiamidate morpholino oligomers efficiently prevent growth of Escherichia coli in vitro and in vivo.](#)
*Objectives Phosphorodiamidate morpholino oligomers (PMOs) are uncharged...*4th November, 2009
AVI BioPharma, Inc., 4574 SW Research Way, Suite 200, Corvallis, OR 97333,- J Antimicrob Chemother. 2009 Nov 1. ([DOI Direct Link](#))
- [Peptide-morpholino conjugate: a promising therapeutic for Duchenne muscular dystrophy.](#)
*Steric-blocking oligos can correct reading frame errors or skip premature...*23rd October, 2009
AVI BioPharma, Corvallis,- Ann N Y Acad Sci. 2009 Sep;1175:55-60. ([DOI Direct Link](#))
- [Antisense targeting of cFLIP sensitizes activated T cells to undergo apoptosis and desensitizes responses to contact dermatitis.](#)

- Contact dermatitis is the result of inflammatory responses mediated by...* 1st August, 2009
 Department of Biology, AVI BioPharma Inc., Corvallis, Oregon, USA.- J Invest Dermatol. 2009 Aug;129(8):1945-53. Epub 2009 Feb 19. ([DOI Direct Link](#))
- [Splicing in the immune system: potential targets for therapeutic intervention by antisense-mediated alternative splicing.](#)
Alternative splicing of pre-mRNA leads to variation in the exons that form... 12th June, 2009
 AVI BioPharma, 4575 SW Research Way, Suite 200, Corvallis, OR 97333, USA.- Curr Opin Mol Ther. 2009 Apr;11(2):124-32.
 - [RNA-based therapeutics--from design to the clinic.](#)
Alternative splicing of pre-mRNA leads to variation in the exons that form... 12th June, 2009
 AVI BioPharma, 4575 SW Research Way, Corvallis, OR 97333, USA.- Curr Opin Mol Ther. 2009 Apr;11(2):107.
 - [Variations in amino acid composition of antisense peptide-phosphorodiamidate morpholino oligomer affect potency against Escherichia coli in vitro and in vivo.](#)
The potency of antisense peptide-phosphorodiamidate morpholino oligomers... 21st April, 2009
 AVI BioPharma, Inc., Corvallis, Oregon, USA.- Antimicrob Agents Chemother. 2009 Feb;53(2):525-30. Epub 2008 Nov 17. ([DOI Direct Link](#))
 - [Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus.](#)
OBJECTIVES: To determine the antiviral activity of phosphorodiamidate... 22nd October, 2008
 AVI BioPharma Inc., 4575 SW Research Way, Corvallis, OR 97333, USA.- J Antimicrob Chemother. 2008 Sep;62(3):555-65. Epub 2008 Jun 19. ([DOI Direct Link](#))
 - [Nucleic acid-based inhibition of flavivirus infections.](#)
The genus Flavivirus in the family Flaviviridae consists of many... 12th December, 2007
 AVI BioPharma Inc.,- Front Biosci. 2008 Jan 1;13:1385-95.
 - [Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing.](#)
Phosphorodiamidate morpholino oligomers (PMO) are synthetic antisense... 19th October, 2007
 AVI BioPharma Inc., Corvallis, Oregon 97333, USA.- J Immunol Methods. 2007 Aug 31;325(1-2):114-26. Epub 2007 Jul 27. ([DOI Direct Link](#))
 - [Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD \(Duchenne muscular dystrophy\) and inhibit murine coronavirus replication in vivo.](#)
The cellular uptake of PMOs (phosphorodiamidate morpholino oligomers) can... 12th October, 2007
 AVI BioPharma Inc., 4575 SW Research Way, Corvallis, OR 97333, USA.- Biochem Soc Trans. 2007 Aug;35(Pt 4):826-8. ([DOI Direct Link](#))
 - [Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity.](#)
Arginine-rich cell-penetrating peptides (CPPs) are promising transporters... 6th October, 2007
 AVI BioPharma, Inc., Corvallis, OR 97333, USA.- Nucleic Acids Res. 2007;35(15):5182-91. Epub 2007 Aug 1. ([DOI Direct Link](#))
 - [Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate.](#)
OBJECTIVE: Conjugation of arginine-rich cell-penetrating peptide (CPP) to... 5th October, 2007
 AVI BioPharma,- Bioconjug Chem. 2007 Jul-Aug;18(4):1325-31. Epub 2007 Jun 21. ([DOI Direct Link](#))
 - [Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells.](#)
Cell penetrating peptides (CPPs) have been shown to enhance the cellular... 28th February, 2007
 AVI BioPharma, Incorporated, 4575 SW Research Way, Corvallis, Oregon- Bioconjug Chem. 2007 Jan-Feb;18(1):50-60. ([DOI Direct Link](#))
 - [Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: dose-response in mice infected with Escherichia coli.](#)
OBJECTIVES: Phosphorodiamidate morpholino oligomers (PMOs) are DNA... 21st February, 2007
 AVI BioPharma, Inc., Corvallis, OR, USA.- J Antimicrob Chemother. 2007 Jan;59(1):66-73. Epub 2006 Oct 31. ([DOI Direct Link](#))

- [Inhibition of multiple subtypes of influenza A virus in cell cultures with morpholino oligomers.](#)
Peptide-conjugated phosphorodiamidate morpholino oligomers (P-PMO) are... 12th December, 2006
 AVI BioPharma Inc., 4575 SW Research Way, Corvallis, OR 97333, USA.- Antimicrob Agents
 Chemother. 2006 Nov;50(11):3724-33. Epub 2006 Sep 11. ([DOI Direct Link](#))

Press Releases on AVI BioPharma:

PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend	23rd November, 2009	PDL BioPharma, Inc.	<i>INCLINE VILLAGE, Nev., Nov. 23 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that NASDAQ has established November 27, 2009 as the ex-dividend date for its \$200</i>
Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update	23rd November, 2009	Wound Management Technologies, Inc.	<i>FORT WORTH, Texas, Nov. 23 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced that it has</i>
Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines	20th November, 2009	Soligenix, Inc.	<i>PRINCETON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), formerly known as DOR BioPharma, Inc., a late-stage biotechnology company,</i>
Soligenix Reports Third Quarter 2009 Financial Results	13th November, 2009	Soligenix, Inc.	<i>-- The granting of Orphan Drug Designation by the FDA's Office of Orphan Products Development for oral BDP (beclomethasone 17,21-dipropionate, or orBecÂ®) for the treatment</i>
PDL BioPharma Announces Special Dividend Payment	12th November, 2009	PDL BioPharma, Inc.	<i>INCLINE VILLAGE, Nev., Nov. 12 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it will pay a \$200 million special dividend to stockholders, with part of the</i>

- [AVI BioPharma gives update on AVI-4658 for Duchenne muscular dystrophy](#)
Pharmacy Choice: Nov 20 2009 11:07PM Matching: avi biopharma
- [AVI BioPharma, Inc. Presents Update on AVI-4658 at TREAT-NMD / NIH International Conference](#)
Individual.com: Nov 20 2009 1:58PM Matching: avi biopharma
- [AVI BioPharma, Inc. Presents Update on AVI-4658 at TREAT-NMD / NIH International Conference](#)
Pharmacy Choice: Nov 19 2009 8:10PM Matching: avi biopharma
- [AVI BioPharma, Inc. Presents Update on AVI-4658 at TREAT-NMD / NIH International Conference](#)
Reuters: Nov 19 2009 1:55PM Matching: avi biopharma
- [AVI BioPharma, Inc. Presents Update on AVI-4658 at TREAT-NMD /](#)
Market Wire via MSN Money: Nov 19 2009 1:21PM Matching: avi biopharma
- [AVI BioPharma \(AVII\) to Present Data for Duchenne Muscular Dystrophy Therapy at TREAT-NMD/NIH Conference](#)
Street Insider: Nov 19 2009 1:40PM Matching: avi biopharma
- [AVI BioPharma, Inc. to Present at Transformational Medical Technologies Initiative \(TMTI\) Industry Day](#)
Pharmacy Choice: Nov 19 2009 4:44AM Matching: avi biopharma
- [AVI BioPharma, Inc. \(AVII\) Presents Update on AVI-4658 at TREAT-NMD/NIH International Conference](#)
BioSpace: Nov 19 2009 7:18PM Matching: avi biopharma
- [AVI BioPharma, Inc. to Present at Transformational Medical Technologies Initiative \(TMTI\) Industry Day](#)
MDLinx: Nov 19 2009 11:21AM Matching: avi biopharma
- [AVI BioPharma, Inc. to Present at Transformational Medical](#)
Market Wire via MSN Money: Nov 18 2009 1:41PM Matching: avi biopharma
- [AVI BioPharma, Inc. to Present at Transformational Medical Technologies Initiative \(TMTI\) Industry Day](#)
Reuters: Nov 18 2009 1:39PM Matching: avi biopharma
- [AVI BioPharma, Inc. to Present at Transformational Medical Technologies Initiative \(TMTI\) Industry Day](#)
Street Insider: Nov 18 2009 1:32PM Matching: avi biopharma
- [AVI BioPharma, Inc. to Present at Transformational Medical Technologies Initiative \(TMTI\) Industry Day](#)
Stockwatch: Nov 18 2009 1:09PM Matching: avi biopharma
- [AVI BioPharma, Inc. to Present at Transformational Medical Technologies Initiative \(TMTI\) Industry Day](#)
Yahoo! Canada: Nov 18 2009 1:26PM Matching: avi biopharma
- [AVI BioPharma, Inc. to Present at Transformational Medical Technologies Initiative \(TMTI\) Industry Day](#)
Freshnews.com: Nov 18 2009 5:53PM Matching: avi biopharma

AVI BioPharma Clinical Trials:



- [Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid](#)



AVI BioPharma Patents:

- 7582615- [Antisense antiviral compound and method for treating arenavirus infection](#)
- 6828105- [Antisense antiviral agent and method for treating ssRNA viral infection](#)
- 6784291- [Splice-region antisense composition and method](#)
- 6764680- [Combined approach to treatment of cancer with hCG vaccines](#)
- 6677153- [Antisense antibacterial method and composition](#)
- 6365577- [p53 antisense agent and method](#)
- 6365351- [Non-invasive method for detecting target RNA](#)
- 6124271- [Method and conjugate for treating H. pylori infection](#)
- 6060246- [Reagent and method for isolation and detection of selected nucleic acid sequences](#)
- 6841542- [Transforming growth factor beta \(TGF-.beta.\) blocking agent-treated stem cell composition and method](#)
- 6869795- [Antisense compositions and cancer-treatment methods](#)
- 7049431- [Antisense antibacterial cell division composition and method](#)
- 7524829- [Antisense antiviral compounds and methods for treating a filovirus infection](#)
- 7507196- [Antisense antiviral compounds and methods for treating a filovirus infection](#)
- 7468418- [Compositions for enhancing transport of molecules into cells](#)
- 7402574- [Antisense composition and method for treating cancer](#)
- 7264925- [Method for analysis of oligonucleotide analogs](#)
- 7238675- [Antisense antibacterial method and composition](#)
- 7115583- [Microbubble compositions and methods for oligonucleotide delivery](#)
- 7094765- [Antisense restenosis composition and method](#)
- 6030941- [Polymer composition for delivering substances in living organisms](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

